Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas.

ABSTRACT:

Background

The efficacy of novel targeted therapies is often tested at the time of tumor recurrence. However, for glioblastoma (GBM) patients, surgical resections at recurrence are performed only in a minority of patients; therefore, molecular data are predominantly derived from the initial tumor. Molecular data of the initial tumor for patient selection into personalized medicine trials can therefore be used only when the specific genetic change is retained in the recurrent tumor.

Methods

In this study we determined whether EGFR amplification and expression of the most common mutation in GBMs (EGFRvIII) is retained at tumor recurrence. Because retention of genetic changes may be dependent on the initial treatment, we only used a cohort of GBM samples that were uniformly tre

SUBMITTER: van den Bent MJ 

PROVIDER: S-EPMC5762005 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature